Hormonal
Weekly subcutaneous semaglutide at 2.4 mg reduces the risk of major adverse cardiovascular events (death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke) in patients with obesity or overweight and preexisting cardiovascular disease, regardless of diabetes status.
If you have heart disease and are overweight or obese, but do not have diabetes, adding once-weekly semaglutide (2.4 mg) to your standard heart care significantly lowers your risk of heart attack, stroke, or heart-related death. The treatment involves a slow buildup of the dose over 16 weeks to manage side effects like nausea. While it works well for most, be aware that gastrointestinal issues are the main reason people stop taking it.
In patients with preexisting cardiovascular disease and overweight or obesity but without diabetes, weekly subcutaneous semaglutide at a dose of 2.4 mg was superior to placebo in reducing the incidence of death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke at a mean follow-up of 39.8 months.
Why this rating
The study is a multicenter, double-blind, randomized, placebo-controlled, event-driven superiority trial with 17,604 patients, published in the New England Journal of Medicine.
Source
Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes
A. Michael Lincoff et al. · New England Journal of Medicine · 2023
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →